Baolingbao Biology Co.,Ltd. (SHE:002286)

Market Cap	3.75B +37.4%
Revenue (ttm)	2.69B +12.6%
Net Income	144.09M +32.1%
EPS	0.39 +26.5%
Shares Out	380.57M
PE Ratio	25.22
Forward PE	n/a
Dividend	0.12 (1.21%)
Ex-Dividend Date	Jul 3, 2025

Volume	5,846,126
Average Volume	13,413,637
Open	9.75
Previous Close	9.88
Day's Range	9.51 - 9.98
52-Week Range	6.45 - 13.40
Beta	0.53
RSI	47.17
Earnings Date	Apr 25, 2026

About Baolingbao Biology

Baolingbao Biology Co.,Ltd. researches and develops, manufactures, and sells a range of functional sugars in China. The company offers prebiotics, such as isomaltooligosaccharides, galactooligosaccharides, fructooligosaccharides, bagasse trisaccharides, and xylooligosaccharides; sugar alcohols and new sugar source products, including erythritol, trehalose, crystalline fructose, alodonose, and maltose; dietary fiber products comprising polydextrose and resistant dextrin; modified, waxy maize, and corn starch products; starch sugar products, incl...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1997
• Employees: 1,395
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 002286

Financial Performance

In 2024, Baolingbao Biology's revenue was 2.40 billion, a decrease of -4.84% compared to the previous year's 2.52 billion. Earnings were 111.16 million, an increase of 105.97%.